Carlsbad, CA, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc (PALI), (“Palisade,” “Palisade Bio” or the “Company”), a clinical-stage biopharmaceutical company focused on developing novel ...
PALI-2108 demonstrated favorable safety and tolerability with no serious adverse events after two weeks of treatment in a difficult-to-treat population Phase 1b data demonstrate endoscopic improvement ...
First three Single Ascending Dose cohorts demonstrated no treatment related adverse events Carlsbad, CA, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc, (Nasdaq: PALI) (“Palisade,” “Palisade Bio” ...
Carlsbad, CA, March 14, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on developing and ...
Palisade Bio (PALI) fell for the second consecutive session on Tuesday after initial data from an early-stage trial for its lead asset PALI-2108 in fibrostenotic Crohn’s disease (FSCD), a severe form ...
TheFly reported on April 8 that Wolfe Research initiated coverage of PALI with an Outperform rating and a $7 price target.
On Thursday, Palisade Bio Inc (NASDAQ:PALI) stock is trading higher with a strong session volume of 26.97 million, compared to an average volume of 107.68k as per data from Benzinga Pro. Palisade Bio ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results